C4'-Substituted-2-Deoxyadenosine Analogs and Methods of Treating HIV
Posted Jun 09 2010 5:00pm
Description of Invention: The invention describes a new use for C4'-methyl-2-dexoyadenosine, a nucleoside analog that has significant activity against HIV-1 and most strains of HIV previously shown to be resistant to other reverse transcriptase nucleoside inhibitor treatments. In vitro experimental results show substantial anti-HIV activity (blocked infectivity) with no observable cytotoxicity in cell culture. Mechanistic studies indicate that this compound blocks DNA synthesis by reverse transcriptase.
Applications: Treatment and prevention of HIV infection
Nucleoside analog against HIV-1 reverse transcriptase with no observable cytotoxicity in cell culture
Potential new treatment for HIV-1 infections including infections by strains of HIV-1 that are resistant to nucleoside reverse transcriptase inhibitors
Development Status: In vitro data can be provided upon request
Meeting Abstract: 8th Annual Symposium for Antiviral Resistance in Richmond, VA, November 11-14, 2007 (Can be provided upon request)
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Cancer Institute HIV Drug Resistance Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize C4' methyl- and C4'-ethyl-substituted-2-deoxyadenosine analogs Please contact John D. Hewes, Ph.D. at 301-435-3121 or firstname.lastname@example.org for more information.
For Additional Information Please Contact: Sally Hu Ph.D., M.B.A. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5606 Fax: 301-402-0220